Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations
Decentralized manufacturing has emerged as a promising approach to improve the accessibility and scalability of cell and gene therapy products, particularly for autologous treatments. This paper proposes a comprehensive Quality Management System (QMS) framework tailored to decentralized cell therapy...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
05 August 2025
|
| In: |
Frontiers in medicine
Year: 2025, Volume: 12, Pages: 1-11 |
| ISSN: | 2296-858X |
| DOI: | 10.3389/fmed.2025.1591751 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fmed.2025.1591751 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1591751/full 
|
| Author Notes: | Heiko von der Leyen, Julio Delgado, Chaya Mazouz, Michael Schmitt and Vered Caplan |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1948488000 | ||
| 003 | DE-627 | ||
| 005 | 20260112122526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260112s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2025.1591751 |2 doi | |
| 035 | |a (DE-627)1948488000 | ||
| 035 | |a (DE-599)KXP1948488000 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Leyen, Heiko E. von der |d 1955- |e VerfasserIn |0 (DE-588)120285169 |0 (DE-627)476237874 |0 (DE-576)292138423 |4 aut | |
| 245 | 1 | 0 | |a Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations |c Heiko von der Leyen, Julio Delgado, Chaya Mazouz, Michael Schmitt and Vered Caplan |
| 264 | 1 | |c 05 August 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht: 05. August 2025 | ||
| 500 | |a Gesehen am 12.01.2026 | ||
| 520 | |a Decentralized manufacturing has emerged as a promising approach to improve the accessibility and scalability of cell and gene therapy products, particularly for autologous treatments. This paper proposes a comprehensive Quality Management System (QMS) framework tailored to decentralized cell therapy manufacturing, integrating current Good Manufacturing Practice (cGMP) principles and regulatory oversight through a centralized Control Site model. The Control Site serves as the regulatory nexus, maintaining POCare Master Files and ensuring consistency across multiple decentralized manufacturing sites. Decentralized manufacturing has the potential to facilitate accessibility for cell and gene therapies. The proposed model leverages automated, closed-system technologies to minimize process variability and hardware deviations, thereby enhancing product quality and regulatory compliance. The Control Site holds functional roles like primary focus point for interaction with regulatory agencies, provision of quality assurance, qualified person (QP) and oversight systems. It also maintains the POCare Master File for the individual POCare GMP manufacturing sites. A standardized GMP manufacturing platform (e.g., deployable as prefabricated units allowing quick expansion) and an overarching training platform should guarantee quality standards. Key regulatory expectations will be discussed, e.g., the demonstration of consistency and comparability, the central role of QP (as proposed in the context of the European Commission’s Pharma strategy), and the Control Site as single point of contact for competent authorities. This approach aims to streamline cell therapy production at or near point of care, supporting rapid and cost-effective clinical implementation. | ||
| 650 | 4 | |a cell and gene therapy | |
| 650 | 4 | |a control site | |
| 650 | 4 | |a decentralized manufacturing | |
| 650 | 4 | |a GMP compliance | |
| 650 | 4 | |a point of care platform | |
| 650 | 4 | |a quality management system | |
| 650 | 4 | |a regulatory oversight | |
| 700 | 1 | |a Delgado, Julio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mazouz, Chaya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 700 | 1 | |a Caplan, Vered |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d Lausanne : Frontiers Media, 2014 |g 12(2025), Artikel-ID 1591751, Seite 1-11 |h Online-Ressource |w (DE-627)789482991 |w (DE-600)2775999-4 |w (DE-576)408729597 |x 2296-858X |7 nnas |a Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations |
| 773 | 1 | 8 | |g volume:12 |g year:2025 |g elocationid:1591751 |g pages:1-11 |g extent:11 |a Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2025.1591751 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1591751/full |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260112 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1948488000 |e 4845302195 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Veröffentlicht: 05. August 2025","Gesehen am 12.01.2026"],"title":[{"title":"Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations","title_sort":"Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations"}],"origin":[{"dateIssuedDisp":"05 August 2025","dateIssuedKey":"2025"}],"person":[{"family":"Leyen","given":"Heiko E. von der","role":"aut","display":"Leyen, Heiko E. von der"},{"family":"Delgado","role":"aut","given":"Julio","display":"Delgado, Julio"},{"display":"Mazouz, Chaya","family":"Mazouz","role":"aut","given":"Chaya"},{"display":"Schmitt, Michael","family":"Schmitt","given":"Michael","role":"aut"},{"role":"aut","given":"Vered","family":"Caplan","display":"Caplan, Vered"}],"relHost":[{"note":["Gesehen am 09.02.2021"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Frontiers in medicine","title":"Frontiers in medicine"}],"origin":[{"publisher":"Frontiers Media","dateIssuedKey":"2014","dateIssuedDisp":"2014-","publisherPlace":"Lausanne"}],"disp":"Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerationsFrontiers in medicine","physDesc":[{"extent":"Online-Ressource"}],"recId":"789482991","part":{"pages":"1-11","year":"2025","volume":"12","text":"12(2025), Artikel-ID 1591751, Seite 1-11","extent":"11"},"id":{"eki":["789482991"],"issn":["2296-858X"],"zdb":["2775999-4"]},"pubHistory":["2014 -"],"titleAlt":[{"title":"FMED"},{"title":"Front. Med."}]}],"physDesc":[{"extent":"11 S.","noteIll":"Illustrationen"}],"recId":"1948488000","id":{"doi":["10.3389/fmed.2025.1591751"],"eki":["1948488000"]},"name":{"displayForm":["Heiko von der Leyen, Julio Delgado, Chaya Mazouz, Michael Schmitt and Vered Caplan"]}} | ||
| SRT | |a LEYENHEIKOIMPLEMENTA0520 | ||